Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice
Open Access
- 11 July 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 153 (2), 269-276
- https://doi.org/10.1111/j.1365-2249.2008.03683.x
Abstract
Summary: Mesenchymal stem cells (MSCs) have the inherent ability to migrate to multiple organs and to exert immunosuppressive activity. The aim of this study was to investigate the anti-arthritogenic effects of interleukin (IL)-10-transduced MSCs (IL-10-MSC) on the development of inflammatory arthritis. DBA/1 mice were immunized with type II collagen (CII) to induce inflammatory arthritis and then injected weekly three times with IL-10-MSCs 21 days after primary immunization. Control mice received vehicle or MSCs alone. Serum anti-CII antibody and T cell response to CII were determined. The results showed that cultured IL-10-MSCs were able to secrete high amounts of IL-10 in vitro. Injection of IL-10-MSCs decreased the severity of arthritis significantly. However, there was no difference in arthritis severity between mice treated with MSC and vehicle alone. Anti-CII antibody titres in the sera and T cell proliferative response to CII in lymph node cells were decreased significantly in mice treated with IL-10-MSCs compared with vehicle-treated mice. Serum IL-6 level was also decreased by the administration of IL-10-MSCs. In contrast, spleen cells of IL-10-MSC-treated mice produced higher amounts of IL-4 than those of control mice. Interestingly, although not as potent as IL-10-MSCs, injection of naive MSCs alone decreased serum levels of IL-6 and anti-CII antibody, while increasing IL-4 production from cultured splenic cells. Taken together, systemic administration of genetically modified MSCs overexpressing IL-10 inhibits experimental arthritis not only by suppressing autoimmune response to CII but also by regulating cytokine production, and thus would be a new strategy for treating rheumatoid arthritis.Keywords
This publication has 38 references indexed in Scilit:
- Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen‐induced arthritisArthritis & Rheumatism, 2007
- Mechanism of Divergent Growth Factor Effects in Mesenchymal Stem Cell DifferentiationScience, 2005
- Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cellsBlood, 2005
- Conversion in vivo from an early dominant Th0/Th1 response to a Th2 phenotype during the development of collagen‐induced arthritisEuropean Journal of Immunology, 1997
- Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin‐10 and interleukin‐4Arthritis & Rheumatism, 1996
- Interleukin‐10 inhibition of the progression of established collagen‐induced arthritisArthritis & Rheumatism, 1996
- Interleukin‐10 functions as an antiinflammatory cytokine in rheumatoid synoviumArthritis & Rheumatism, 1996
- High level of interleukin‐10 production by the activated t cell population within the rheumatoid synovial membraneArthritis & Rheumatism, 1995
- Immunoregulatory role of interleukin 10 in rheumatoid arthritis.The Journal of Experimental Medicine, 1994
- Macrophage deactivation by interleukin 10.The Journal of Experimental Medicine, 1991